Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma

Glioblastoma is the most common and aggressive primary tumor of the central nervous system with poor outcome. Current gold standard treatment is surgical resection followed by a combination of radio- and chemotherapy. Efficacy of temozolomide (TMZ), the primary chemotherapeutic agent, depends on the...

Description complète

Détails bibliographiques

Auteurs principaux:	Xinyu Han, Mohammed O.E. Abdallah, Peter Breuer, Fabian Stahl, Yousuf Bakhit, Anna-Laura Potthoff, Barbara E.F. Pregler, Matthias Schneider, Andreas Waha, Ullrich Wüllner, Bernd O. Evert
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2023-10-01
Collection:	Neoplasia: An International Journal for Oncology Research
Sujets:	CRISPR/Cas9 technology MGMT Temozolomide Glioblastoma
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S1476558623000532
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!